Federal Circuit upholds invalidity decision on Humira patent

22-08-2014

Federal Circuit upholds invalidity decision on Humira patent

Rustle / Shutterstock.com

The US Court of Appeals for the Federal Circuit yesterday (August 21) upheld a lower court’s decision that a patent covering rheumatoid arthritis drug Humira (adalimumab) is invalid.


Federal Circuit, Humira, AbbVie, The Mathilda and Terence Kennedy Institute of Rheumatology Trust, patent invalidity

More on this story

AbbVie triumphs in Humira case
02-07-2013

LSIPR